Pfiz­er-backed Vedan­ta Bio­sciences lands $106M for PhI­II in C. diff, PhII in IBD

Vedan­ta Bio­sciences has se­cured the cash it needs to run a Phase III in Clostrid­ioides dif­fi­cile and a mid-stage tri­al in ul­cer­a­tive col­i­tis, with run­way through 2025, CEO Bernat Olle told End­points News.

The mi­cro­bio­me biotech nabbed $106.5 mil­lion to test whether VE303 can work for pre­vent­ing re­cur­rent C. diff, which leads to in­flam­ma­tion of the colon, with a dif­fer­ent ap­proach than Fer­ring Phar­ma­ceu­ti­cals’ re­cent­ly ap­proved fe­cal-based drug im­plant Re­by­ota and Seres Ther­a­peu­tics’ can­di­date, set for an FDA ap­proval de­ci­sion on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER